Ignite Creation Date:
2024-05-06 @ 2:30 PM
Last Modification Date:
2024-10-26 @ 1:31 PM
Study NCT ID:
NCT04331626
Status:
UNKNOWN
Last Update Posted:
2020-04-02
First Post:
2020-03-31
Brief Title:
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Organization Data
Organization:
Henan Cancer Hospital
Class:
OTHER_GOV
Study ID:
2019090507
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Henan Cancer Hospital
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None